Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Cathie Wood Just Made a Big Bet on Recursion Pharmaceuticals Stock. Will It Pay Off?


Cathie Wood can't get enough of Recursion Pharmaceuticals (NASDAQ: RXRX) stock. Through her Ark Innovation ETF, the maverick growth stock portfolio manager bought shares of the biotech three times, expanding her position from a mere 61,000 shares to roughly 4 million by Nov. 14. When news of her purchasing first broke, the company's stock rose by 30% over the following days.

But Wood is known for making huge bets on potentially disruptive businesses, and it's a fact that sometimes chasing the big new thing doesn't pan out as intended. Let's explore what's driving her decision with this stock, and make a few predictions about whether it'll prove to be a smart investment in a few years from now.

Cathie Wood's strategy is to invest in companies with big ideas that plan to use cutting-edge technology to reshape their markets and industries with new paradigms.

Continue reading


Source Fool.com

Like: 0
Share

Comments